Treatments using BRAF/MEKi (Figure 2A and Movie S3) or HCT (Figure 2B and Movie S4), alone, resulted in a re-establishment of initial tumor volume, prior to the end of the study period, with HCT inducing resistance far earlier than BRAF/MEKi. The gene discussed is BRAF; the disease is neoplasm.